5‐ASA showed no clear difference in clinical relapse compared with no treatment (low certainty).
5‐ASA showed no clear difference in clinical relapse compared with purine antimetabolites (low certainty).
It is very uncertain whether 5‐ASAs changes clinical relapse compared with anti TNF‐ɑ (very low certainty).
5‐ASAs probably leads to lower clinical relapse compared with placebo (moderate certainty).
High dose 5‐ASA showed no clear difference in clinical relapse compared with low dose 5‐ASA (moderate certainty).
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes clinical relapse (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
Probiotics showed no clear difference in clinical relapse (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).